Seeking Alpha

Aratana Therapeutics (PETX)

  • Oct. 14, 2013, 6:30 AM
    • The acquisition is expected to significantly accelerate Aratana's (PETX) pathway toward becoming a commercial-stage pet therapeutics company.
    • Aratana will pay to Vet $30M in cash, issue 625K shares of common stock, and issue a promissory note for $3M with a maturity date of December 31, 2014. Aratana will also pay up to $5M cash upon the achievement of certain regulatory and manufacturing milestones for the B-cell lymphoma product.
    • Aratana also said that it has entered into a share purchase agreement providing for $19.75M of common shares - 1,234,375 shares at $16.00 per share.
    | Comment!
Visit Seeking Alpha's
PETX vs. ETF Alternatives
Company Description
Aratana Therapeutics Inc is a development-stage biopharmaceutical company. It is engaged in licensing, development and commercialization of prescription medicines forcompanion animals.
Sector: Healthcare
Industry: Biotechnology
Country: United States